Phase 3 N=545 Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Lymphoma
Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=156 Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma
Ann Arbor Stage III Grade 1 Follicular Lymphoma · Ann Arbor Stage III Grade 2 Follicular Lymphoma · Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma
Primary: Number of Participants With Best Overall Disease Response — 0; 56; 17; 8 Participants
Phase 2 N=81 Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
Lymphoma
Primary: Percentage of Participants With Indolent NHL Achieving CR or Partial Response (PR) According to International Response Criteria for NHL — 66.7 Percentage of Participants
Phase 2 N=37 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Response Rate — 29 percentage of participants
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 2 N=36 Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
Lymphoma
Primary: Assessment of Tumor Response — 30.3; 54.5 percentage of participants
Phase 2 N=125 Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
Follicular Lymphoma · Small Lymphocytic Lymphoma · Lymphoplasmacytic Lymphoma
Primary: Overall Response Rate — 57.6 percentage of participants — p=< 0.0001
Phase 2 N=43 Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Non-Hodgkins Lymphoma
Primary: Percentage of Participants With Response — 23.3 percentage of participants
Phase 2 N=79 Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Leukemia · Lymphoma
Primary: Maximum Tolerated Dose — 1.8; 1.5 mg/m^2 of Bortezomib
Phase 2 N=20 Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma · Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants
Phase 2 N=30 Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Lymphoma
Primary: Overall Response Rate (Complete and Partial Response) — 46 percentage of participants
Phase 2 N=12 Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
Lymphoma, Non-Hodgkin
Primary: Optimal Bendamustine Dosage for Further Studies — 60 mg/m^2
Phase 2 N=158 A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Follicular Lymphoma · Marginal Zone Lymphoma · Indolent Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment — 92; 69 percentage of participants
Phase 2 N=129 A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
Indolent Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 59.7 percentage of participants — p=<=0.0001
Phase 2 N=217 A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin's
Primary: Participants Categorized by Best Response as Determined by Central Review — 7; 21; 40; 71 Participants
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Phase 2 N=77 Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…
Phase 2 N=66 Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Grade 3a Follicular Lymphoma · Recurrent Follicular Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide When Given With Obinutuzumab Defined as the Highest Dose Level Have Been Treated With Less Than 2 Instances of Dose Limiting…
Phase 2 N=31 Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Low-Grade Lymphoma
Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants
Phase 2 N=46 S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Phase 2 N=87 S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Lymphoma
Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants
Phase 3 N=358 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Lymphoma, Non-Hodgkin
Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…
Phase 2 N=67 Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
Lymphoma
Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants
Phase 2 N=25 A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Primary: Overall Response Rate — 12 Participants — p=0.044
Phase 2 N=18 Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Indolent Non-Hodgkin's Lymphoma · Follicular Lymphoma · Small Lymphocytic Lymphoma
Primary: Overall Safety of Idelalisib — 88.9; 27.8; 55.6; 83.3 percentage of participants
Phase 2 N=23 PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Primary: Clinical Response Rate — 1; 7; 0; 8 Participants
Phase 2 N=11 Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
High Risk Non-Hodgkin's Lymphoma
Primary: Assess the Efficacy of Combination Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma — 6 Participants
Phase 1 N=11 Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma
Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lymphoma, Mantle-Cell
Primary: Maximum Tolerated Dose — 2.24 mg/m^2
Phase 2 N=226 Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Lymphoma, Non-Hodgkin
Primary: Objective Response Rate (ORR) Based on Independent Review-Part A — 43.75; 27.08 percentage of participants — p=0.0001
Phase 2 N=68 Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas
Non-Hodgkin's Lymphoma
Primary: Percentage of Patients With Complete Response to the Combination Chemotherapy — 75.0; 23.0 Percentage of participants